AUTHOR INDEX TO VOLUME 7

Abell M, 110A
Alderman JL, 47A
Allen A, 103A
Anderson CR, 115A
Anderson JL, 103A
Arnett D, 119A

Bala Subramanian V, 25
Barbarash RA, 41A
Barbetti P, 46A, 53A
Beaty R, 51A
Becker R, 54A
Berry P, 181
Berzon RA, 203
Bigelow GE, 65
Birtwistle D, 139
Blackmon P, 115A
Bleicher R, 109A
Bolash NK, 118A
Borgen LA, 106A
Boxx LS, 104A
Bresnick PA, 17
Breton L, 51A
Buhay N, 154
Buonagura AM, 115A
Butterworth B, 43A
Byrne BJ, 48A

Caldwell RW, 25
Campanaro E, 111A
Carey LA, 111A
Carlson J, 106A
Cavanaugh S, 117A
Chandler J, 46A
Chandler JF, 114A
Chaponis RJ, 17
Cocchetto D, 174
Cocchetto DM, 121
Cone KR, 107A
Cook ME, 115A
Craig MT, 104A

Davidson JA, 114A
Davis DD, 42A
DeGaetano C, 52A
Dockhorn DW, 45A, 102A
Dornbierer M, 46A

Due DL, 48A
Durbin PM, 107A

Edgar PP, 147
Edwards LD, 17
Enas GG, 193

Faich GA, 107A
Falk JI, 53A
Felch L, 65
Ferzola N, 119A
Flanagan D, 111A
Funderburk FR, 3, 65

Gergits MA, 47A
Gibbons-White S, 111A
Glasser S, 119A
Gorski CM, 109A
Grable D, 41A
Griffiths CEM, 101A
Griffiths RR, 65
Grove PL, 113A

Haire WD, 109A
Halloran L, 49A, 118A
Harman E, 51A
Harvey M, 115A
Hawkins C, 119A
Hendeles L, 51A
Hernadi E, 110A
Herzog H, 104A
Himmel JK, 116A
Hyland D, 44A, 116A

Jeyashree S, 25
Johnston DB, 31

Kahn SM, 107A
Karagounis LA, 103A
Kessler DA, 183
Koehn KR, 107A
Koffer H, 107A
Kotulak GD, 109A

Lange W, 54A, 102A, 114A
Lea DE, 108A, 112A
Liang M, 112A

Journal of Clinical Research and Pharmacoepidemiology 7, 257–258 (1993)

© 1993 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0889-5813/93/$6.00

Liebson IA, 65
Lindsey T, 44A
Liu HH, 118A
Lubina JA, 123

Mackenzie A, 65
Magid A, 105A
Margitić SE, 243
Martin M, 161
McClees NJ, 109A
McCoy H, 106A
McDermond T, 114A
Miller CK, 41A
Molino L, 51A
Morgan JP, 3
Myers T, 106A

Nagarajan R, 25
Nagle B, 50A
Nappi A, 50A
Neace S, 101A

Ogle C, 101A

Papke A, 77
Papke RA, 44A, 116A
Parmentier J, 127
Parry JL, 105A
Pederson J, 51A
Peng A, 49A
Pietruszka MH, 99A
Powers F, 110A
Price M, 54A, 114A
Priesmeyer C, 119A

Resnick G, 46A
Resnick GD, 53A
Roskelley M, 103A
Roulia V, 101A
Routh I, 105A
Rowan AJ, 43A, 52A

Santoro J, 50A
Saunders M, 130
Schwartz AM, 100A
Schwartz R, 41A
Searight HR, 41A
Seeley P, 111A
Shanmugam M, 25
Shellabarger S, 102A
Simeon GP, 203
Simonyi LK, 41A
Simpson RL Jr, 203
Sims MP, 43A
Sirgo MA, 49A
Stagg A, 127
Stephens LC, 109A
Stevenson JG, 41A
Steward N, 54A
Strickler SW, 51A
Summerfelt A, 3
Summers K, 103A
Swarbrick J, 127

Tilson HH, 233
Toscani M, 46A, 53A
Townsend KC, 113A
Tucker R, 101A
Tuttle RR, 25

Vien C, 111A
Von Tress M, 54A

Wallin JD, 115A
Weinhold LL, 3
Weiss RR, 17
West T, 119A

Young LM, 113A

Zanecchia D, 54A
Zerbe RL, 193

SUBJECT INDEX TO VOLUME 7

ABBREVIATIONS
The PF (Pitfalls) of B (Brevity), 77

ABSTRACTS
ACP Spring 1992 Poster Abstracts, 41A-55A
ACP Spring 1993 Poster Abstracts, 99A-120A
Circadian Rhythm of Erythropoietin in Humans, 99A
The Clinical Quantification of Photoaging, 101A
Clinical Research in the Group Practice Setting, 101A
Clinical Trial Management by a Hospital Pharmacy-Based Clinical Research Division, 41A
Comprehension and Recall of the Informational Consent of the Informed Consent Document: An Evaluation of 168 Patients in a Controlled Clinical Trial, 41A
Computer-Automated QA for Phase I/II Clinical Trials, 102A
Confidentiality Issues, Results, and Demographics in Reporting Research Subjects' Laboratory Results, 47A
Design Considerations for Anti-Hypertensive Trials in the Elderly, 49A
Direct-From-Patient-Information[SM] (DFPI). A Unique Concept for Clinical and Marketing Research, 102A
Does Entry into Thrombolysis Trials Adversely Affect Time-to-Treatment? A Pilot Comparison in an Unblinded, Non-randomized, Parallel Group Study and Nonstudy Patients, 103A
Drug Inventory Utilizing Wordperfect 5.1's Table Feature, 44A
Elderly Population in Sequestered Clinical Trials, 104A
Emergency Medicine Research in the Prehospital Setting: Strategies of the Brain Resuscitation Clinical Trial, 104A
Entry-Level Clinical Research Associate Training Course, 105A
Establishing an Effective Communication System for Decentralized Monitors, 106A
"False Positive" Urine Screen for Opiates Following Consumption of Poppy Seed Muffins, 106A
Global Project Management: A Clinical Research Organization Perspective, 53A
Handling Waste in the Clinical Research Setting, 46A
How to Assist the Paper Flow in Conducting Clinical Research Studies, 51A
How to Develop a Relational Database to Expedite the Investigator Selection Process for Clinical Trials, 107A
How to Implement a Phase I Protocol, 52A
Innovative Approaches to the Conduct of Large-Scale Controlled Clinical Trials, 107A
Inpatient Pharmacokinetic Studies: Improving Safety, 108A
Integration of a Continuous Quality Improvement Process at an Investigative Site, 54A
Investigator Reference Guide Study, 109A
Keying Case Report Form Design to Medical Behavior and Medical Documentation Practices, 42A
Maximize Subject Enrollment, Minimize Time and Effort: Get the Fax, 109A
Measurement of Recovery Time as an Endpoint for Exercise Challenges in Asthma, 51A
A Microcomputer-Assisted Methodology for the Selection of Matched Controls in a Multisite Case-Control Study, 100A
Multicenter Trial Strategies: An Audio/Visual Approach to Augment Study Personnel Training, 46A
A New High Speed Monitoring and Data Entry System, 45
Ongoing Database Creation, 110A

Journal of Clinical Research and Pharmacoepidemiology 7, 259–259-266 (1993)

© 1993 Associates of Clinical Pharmacology

Published by Elsevier Science Publishing Co., Inc.
655 Avenue of the Americas, New York, NY 10010

0889-5813/93/$6.00

Organizational Challenges in SWAT Project Management, 43A
Patient Satisfaction with Participation in a Clinical Trial, 48A
Patient's Perception of Financial Impact of HIV Treatment, 111A
Phase IIIB Clinical Trials: A Management Strategy for the Nineties, 111A
Practically Interfacing . . . The Clinical Investigations Unit, 112A
Prevention is the Best Medicine: A Proactive Approach to a Quality, Analyzable Database, 113A
Quality Assurance and the Implementation of SOPs During Clinical Trials, 113A
Quality of Life in the Elderly Patient After Open Heart Surgery, 47A
Readability of the Patients' Informed Consent: A Continuing Problem in Clinical Trials, 54A
Reducing Case Report Form Corrections Through Use of a Standardized Case Report Form Analysis System, 114A
Remote Entry to Integrated Clinical Project Database: On-Line Reporting of Clinical Trial Site Visit Information by Clinical Research Associates, 50A
Skills Assessment of Clinical Research Associates (CRAs), 49
Skin Test Documentation: A Tape Transfer Method, 114A
Source Documentation in the Form of Protocol-Specific Clinic Visit Sheets, 115A
A Standardized Format for On-Site Monitoring Trip Reports, 52A
Techniques for Ensuring Patient Compliance Through Study Design and Investigator Site-Based Management, 115A
Telephone Log Survey: Needs, Usage, and Proposed Uniform Method, 116A
Time Management in the Research Center: Can We Handle This Protocol?, 116A
Training for Submission of Quality Laboratory Specimens, 117A
Use of a Communication Tool to Facilitate Clinical Trials in the Hospital Setting, 118A
Use of FAX Technology for In-House Monitoring of CRFs, 43A
Use of Project-Specific Development Plans for CRA Training, 118A
Why Do Patients Participate in Clinical Research?, 119A
Why Do Patients Respond to Newspaper Advertisements for Clinical Trials?, 119A

ACRONYMS
The PF (Pitfalls) of B (Brevity), 77

ADINAZOLAM
Behavioral Evaluation of Drugs: A Comparison of the Behavioral Effects of Adinazolam and Lorazepam, 65

ADVERSE EVENT REPORTING
Commentary, 181
Introducing MEDWatch: A New Approach to Reporting Medication and Device Adverse Effects and Product Problems, 183

AGED. *See* ELDERLY

ANALGESIA
Reversal of Effects of Morphine by Nalmefene, 25

ANTIEMETIC
Lessons Learned From Coordinating a Pivotal Clinical Trial, 31

ASTHMA
Measurement of Recovery Time as an Endpoint for Exercise Challenges in Asthma, 51A

BEHAVIORAL ASSESSMENTS
Behavioral Evaluation of Drugs: A Comparison of the Behavioral Effects of Adinazolam and Lorazepam, 65

BIBLIOGRAPHY
Quality of Life Bibliography and Indexes: 1992 Update, 203

BRAIN RESUSCITATION
Emergency Medicine Research in the Prehospital Setting: Strategies of the

Brain Resuscitation Clinical Trial, 104A

CANDIDA VAGINITIS
Candida Vaginitis: Signs and Symptoms Aid Women's Self-Recognition, 17

CASE REPORT FORMS
Keying Case Report Form Design to Medical Behavior and Medical Documentation Practices, 42A
Reducing Case Report Form Corrections Through Use of a Standardized Case Report Form Analysis System, 114A
Use of FAX Technology for In-House Monitoring of CRFs, 43A

CIRCADIAN RHYTHM
Circadian Rhythm of Erythropoietin in Humans, 99A

CLINICAL RESEARCH ASSOCIATES
Entry-Level Clinical Research Associate Training Course, 105A
Remote Entry to Integrated Clinical Project Database: On-Line Reporting of Clinical Trial Site Visit Information by Clinical Research Associates, 50A
Skills Assessment of Clinical Research Associates (CRAs), 49
Use of Project-Specific Development Plans for CRA Training, 118A

COMMUNICATION
Maximize Subject Enrollment, Minimize Time and Effort: Get the Fax, 109A
The PF (Pitfalls) of B (Brevity), 77
Phone Tag: The People's Sport for the '90s, 121
Telephone Log Survey: Needs, Usage, and Proposed Uniform Method, 116A
Use of a Communication Tool to Facilitate Clinical Trials in the Hospital Setting, 118A
Use of FAX Technology for In-House Monitoring of CRFs, 43A

COMMUNICATION SYSTEMS
Establishing an Effective Communication System for Decentralized Monitors, 106A

CONDUCT
Innovative Approaches to the Conduct of Large-Scale Controlled Clinical Trials, 107A

CONFIDENTIALITY
Confidentiality Issues, Results, and Demographics in Reporting Research Subjects' Laboratory Results, 47A

CONTROLS, MATCHED
A Microcomputer-Assisted Methodology for the Selection of Matched Controls in a Multisite Case-Control Study, 100A

DATA ENTRY
A New High Speed Monitoring and Data Entry System, 45

DATABASES
How to Develop a Relational Database to Expedite the Investigator Selection Process for Clinical Trials, 107A
Ongoing Database Creation, 110A
Prevention is the Best Medicine: A Proactive Approach to a Quality, Analyzable Database, 113A
Remote Entry to Integrated Clinical Project Database: On-Line Reporting of Clinical Trial Site Visit Information by Clinical Research Associates, 50A

DIAGNOSIS, DEFINITIVE
Candida Vaginitis: Signs and Symptoms Aid Women's Self-Recognition, 17

DIRECT-FROM-PATIENT-INFORMATION℠
Direct-From-Patient-Information℠ (DFPI). A Unique Concept for Clinical and Marketing Research, 102A

DOCUMENTATION, SOURCE
Source Documentation in the Form of Protocol-Specific Clinic Visit Sheets, 115A

DOCUMENTATION, STUDY
How to Assist the Paper Flow in Conducting Clinical Research Studies, 51A

DOCUMENTATION ERRORS
Investigator Reference Guide Study, 109A

DRUG ABUSE
Confidentiality Issues, Results, and Demographics in Reporting Research Subjects' Laboratory Results, 47A

DRUG INVENTORY
Drug Inventory Utilizing Wordperfect 5.1's Table Feature, 44A

DRUG SCREENING
'False Positive' Urine Screen for Opiates Following Consumption of Poppy Seed Muffins, 106A

EDUCATION/TRAINING
Associates of Clinical Pharmacology Continuing Education Curriculums, 87
Entry-Level Clinical Research Associate Training Course, 105A
Lessons Learned From Coordinating a Pivotal Clinical Trial, 31
The PF (Pitfalls) of B (Brevity), 77
The Role of the Coordinating Center Project Manager in a Multicenter Clinical Trial, 243
Use of Project-Specific Development Plans for CRA Training, 118A

ELDERLY
Design Considerations for Anti-Hypertensive Trials in the Elderly, 49A
Elderly Population in Sequestered Clinical Trials, 104A
Quality of Life in the Elderly Patient After Open Heart Surgery, 47A

EMERGENCY MEDICINE
Emergency Medicine Research in the Prehospital Setting: Strategies of the Brain Resuscitation Clinical Trial, 104A

ERYTHROPOIETIN
Circadian Rhythm of Erythropoietin in Humans, 99A

EUROPEAN COMMON MARKET REGULATIONS
A Comparison of U.S. and E.C. Preclinical Requirements as Addressed at the First International Conference on Harmonization (ICH1), 147
FDA-E.C. Harmonization Effects in the Area of GMPs, 154
Harmonization and Registration Procedures Within the E.C.: A European Perspective, 139
The Impact of European Common Market Regulations on the World Pharmaceutical Industry, 127
Impact of the E.C. Regulations on the World Pharmaceutical Industry—A Japanese Perspective, 161
Round Table Summary Discussion, 174
United States Trade Perspectives on European Community Developments, 130

EXPERIMENTAL DESIGN PRINCIPLES
Untangling a Safety Controversy: Pressor Effects of Phenylpropanolamine, 3

GLOBAL CLINICAL DEVELOPMENT
Global Project Management: A Clinical Research Organization Perspective, 53A

GROUP PRACTICE
Clinical Research in the Group Practice Setting, 101A

HARMONIZATION
A Comparison of U.S. and E.C. Preclinical Requirements as Addressed at the First International Conference on Harmonization (ICH1), 147
FDA-E.C. Harmonization Effects in the Area of GMPs, 154
Harmonization and Registration Procedures Within the E.C.: A European Perspective, 139
Round Table Summary Discussion, 174

HEALTH-RELATED QUALITY OF LIFE MEASURES
Quality of Life Bibliography and Indexes: 1992 Update, 203

HEPATITIS B
Confidentiality Issues, Results, and Demographics in Reporting Research Subjects' Laboratory Results, 47A

HUMAN IMMUNODEFICIENCY VIRUS (HIV)
Confidentiality Issues, Results, and Demographics in Reporting Research Subjects' Laboratory Results, 47A
Patient's Perception of Financial Impact of HIV Treatment, 111A

HYPERTENSION
Design Considerations for Anti-Hypertensive Trials in the Elderly, 49A

INDEXES
Quality of Life Bibliography and Indexes: 1992 Update, 203

INDUSTRY/RESEARCH COLLABORATION
Lessons Learned From Coordinating a Pivotal Clinical Trial, 31

INFORMED CONSENT
Comprehension and Recall of the Informational Consent of the Informed Consent Document: An Evaluation of 168 Patients in a Controlled Clinical Trial, 41A
Readability of the Patients' Informed Consent: A Continuing Problem in Clinical Trials, 54A

INITIALS
The PF (Pitfalls) of B (Brevity), 77

INPATIENT STUDIES
Inpatient Pharmacokinetic Studies: Improving Safety, 108A

INTERIM ANALYSES
A Paradigm for Interim Analyses in Controlled Clinical Trials, 193

INTERNAL MARKETS
United States Trade Perspectives on European Community Developments, 130

INVESTIGATOR REFERENCE GUIDE
Investigator Reference Guide Study, 109A

INVESTIGATOR SELECTION
How to Develop a Relational Database to Expedite the Investigator Selection Process for Clinical Trials, 107A

JAPAN
Impact of the E.C. Regulations on the World Pharmaceutical Industry—A Japanese Perspective, 161
Round Table Summary Discussion, 174

LORAZEPAM
Behavioral Evaluation of Drugs: A Comparison of the Behavioral Effects of Adinazolam and Lorazepam, 65

MANAGEMENT
Innovative Approaches to the Conduct of Large-Scale Controlled Clinical Trials, 107A
Phase IIIB Clinical Trials: A Management Strategy for the Nineties, 111A
Practically Interfacing . . . The Clinical Investigations Unit, 112A
The Role of the Coordinating Center Project Manager in a Multicenter Clinical Trial, 243

MARKETING RESEARCH
Direct-From-Patient-Information^{SM} (DFPI). A Unique Concept for Clinical and Marketing Research, 102A

MEDWatch
Commentary, 181
Introducing MEDWatch: A New Approach to Reporting Medication and Device Adverse Effects and Product Problems, 183

MONITORS
Establishing an Effective Communication System for Decentralized Monitors, 106A

MORPHINE SCREENING
"False Positive" Urine Screen for

Opiates Following Consumption of Poppy Seed Muffins, 106A

MULTICENTER STRATEGIES
Multicenter Trial Strategies: An Audio/Visual Approach to Augment Study Personnel Training, 46A
The Role of the Coordinating Center Project Manager in a Multicenter Clinical Trial, 243

NALMEFENE
Reversal of Effects of Morphine by Nalmefene, 25

NARCOSIS
Reversal of Effects of Morphine by Nalmefene, 25

NEWSPAPER ADVERTISEMENTS
Why Do Patients Participate in Clinical Research?, 119A

OPERATIONS
The Role of the Coordinating Center Project Manager in a Multicenter Clinical Trial, 243

OPIATE SCREENING
"False Positive" Urine Screen for Opiates Following Consumption of Poppy Seed Muffins, 106A

OPIOID ANTAGONIST
Reversal of Effects of Morphine by Nalmefene, 25

PAPERWORK
How to Assist the Paper Flow in Conducting Clinical Research Studies, 51A

PARTICIPATION
Patient Satisfaction with Participation in a Clinical Trial, 48A
Why Do Patients Respond to Newspaper Advertisements for Clinical Trials?, 119A

PATIENT COMPLIANCE
Techniques for Ensuring Patient Compliance Through Study Design and Investigator Site-Based Management, 115A

PATIENT PARTICIPATION
Why Do Patients Participate in Clinical Research?, 119A

PATIENT SATISFACTION
Patient Satisfaction with Participation in a Clinical Trial, 48A

PERSONNEL TRAINING
Multicenter Trial Strategies: An Audio/Visual Approach to Augment Study Personnel Training, 46A

PHASE I/II DATA MANAGEMENT/MAINTENANCE
Computer-Automated QA for Phase I/II Clinical Trials, 102A

PHASE I IMPLEMENTATION
How to Implement a Phase I Protocol, 52A

PHASES
The Role of the Coordinating Center Project Manager in a Multicenter Clinical Trial, 243

PHENYLPROPANOLAMINE
Untangling a Safety Controversy: Pressor Effects of Phenylpropanolamine, 3

PHONE TAG
Phone Tag: The People's Sport for the '90s, 121

PHOTOAGING
The Clinical Quantification of Photoaging, 101A

PRECLINICAL REQUIREMENTS
A Comparison of U.S. and E.C. Preclinical Requirements as Addressed at the First International Conference on Harmonization (ICH1), 147

PROJECT MANAGER
The Role of the Coordinating Center Project Manager in a Multicenter Clinical Trial, 243

QUALITY
Training for Submission of Quality Laboratory Specimens, 117A

QUALITY IMPROVEMENT PROCESS
Integration of a Continuous Quality Improvement Process at an Investigative Site, 54A

QUALITY OF LIFE
Behavioral Evaluation of Drugs: A Comparison of the Behavioral Effects of Adinazolam and Lorazepam, 65
Quality of Life Bibliography and Indexes: 1992 Update, 203
Quality of Life in the Elderly Patient After Open Heart Surgery, 47A

REGISTRATION
Harmonization and Registration Procedures Within the E.C.: A European Perspective, 139

REGULATORY AGENCIES
Commentary, 181
FDA-E.C. Harmonization Effects in the Area of GMPs, 154
Harmonization and Registration Procedures Within the E.C.: A European Perspective, 139
Impact of the E.C. Regulations on the World Pharmaceutical Industry—A Japanese Perspective, 161
Introducing MEDWatch: A New Approach to Reporting Medication and Device Adverse Effects and Product Problems, 183
Round Table Summary Discussion, 174
United States Trade Perspectives on European Community Developments, 130

REGULATORY DECISION-MAKING
Behavioral Evaluation of Drugs: A Comparison of the Behavioral Effects of Adinazolam and Lorazepam, 65

SAFETY
Inpatient Pharmacokinetic Studies: Improving Safety, 108A
Untangling a Safety Controversy: Pressor Effects of Phenylpropanolamine, 3

SELF-RECOGNITION
Candida Vaginitis: Signs and Symptoms Aid Women's Self-Recognition, 17

SKIN LESIONS
The Clinical Quantification of Photoaging, 101A

SKIN TESTING
Skin Test Documentation: A Tape Transfer Method, 114A

STANDARD OPERATING PROCEDURES
Quality Assurance and the Implementation of SOPs During Clinical Trials, 113A

SWAT PROJECT MANAGEMENT
Organizational Challenges in SWAT Project Management, 43A

TECHNOLOGY
A New High Speed Monitoring and Data Entry System, 45
Drug Inventory Utilizing Wordperfect 5.1's Table Feature, 44A
Maximize Subject Enrollment, Minimize Time and Effort: Get the Fax, 109A
Use of FAX Technology for In-House Monitoring of CRFs, 43A

TELEPHONE LOG
Telephone Log Survey: Needs, Usage, and Proposed Uniform Method, 116A

THROMBOLYSIS
Does Entry into Thrombolysis Trials Adversely Affect Time-to-Treatment? A Pilot Comparison in an Unblinded, Non-randomized, Parallel Group Study and Nonstudy Patients, 103A

TIME MANAGEMENT
Time Management in the Research Center: Can We Handle This Protocol?, 116A

TRIP REPORT FORMAT
A Standardized Format for On-Site Monitoring Trip Reports, 52A

TUBAL LIGATION
Reversal of Effects of Morphine by Nalmefene, 25

WASTE MANAGEMENT
Handling Waste in the Clinical Research Setting, 46A